• Something wrong with this record ?

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

JW. Goldman, MC. Garassino, Y. Chen, M. Özgüroğlu, M. Dvorkin, D. Trukhin, G. Statsenko, K. Hotta, JH. Ji, MJ. Hochmair, O. Voitko, L. Havel, A. Poltoratskiy, G. Losonczy, N. Reinmuth, N. Patel, PJ. Laud, N. Shire, H. Jiang, L. Paz-Ares

. 2020 ; 149 (-) : 46-52. [pub] 20200910

Language English Country Ireland

Document type Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21019919

OBJECTIVES: In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall survival (primary endpoint) versus EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) at the interim analysis. Here we report patient-reported outcomes (PROs). MATERIALS AND METHODS: Treatment-naïve patients with ES-SCLC received 4 cycles of durvalumab plus EP every 3 weeks followed by maintenance durvalumab every 4 weeks until progression, or up to 6 cycles of EP every 3 weeks. PROs, assessed with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) version 3 and its lung cancer module, the Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), were prespecified secondary endpoints. Changes from baseline to disease progression or 12 months in prespecified key disease-related symptoms (cough, dyspnea, chest pain, fatigue, appetite loss) were analyzed with a mixed model for repeated measures. Time to deterioration (TTD) of symptoms, functioning, and global health status/quality of life (QoL) from randomization was analyzed. RESULTS: In the durvalumab plus EP and EP arms, 261 and 260 patients were PRO-evaluable. Patients in both arms experienced numerically reduced symptom burden over 12 months or until progression for key symptoms. For the improvements from baseline in appetite loss, the between-arm difference was statistically significant, favoring durvalumab plus EP (difference, -4.5; 99% CI: -9.04, -0.04; nominal p = 0.009). Patients experienced longer TTD with durvalumab plus EP versus EP for all symptoms (hazard ratio [95% CI] for key symptoms: cough 0.78 [0.600‒1.026]; dyspnea 0.79 [0.625‒1.006]; chest pain 0.76 [0.575‒0.996]; fatigue 0.82 [0.653‒1.027]; appetite loss 0.70 [0.542‒0.899]), functioning, and global health status/QoL. CONCLUSION: Addition of durvalumab to first-line EP maintained QoL and delayed worsening of patient-reported symptoms, functioning, and global health status/QoL compared with EP.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019919
003      
CZ-PrNML
005      
20230109125907.0
007      
ta
008      
210728s2020 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.lungcan.2020.09.003 $2 doi
035    __
$a (PubMed)32961445
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Goldman, Jonathan W $u David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: jwgoldman@mednet.ucla.edu
245    10
$a Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study / $c JW. Goldman, MC. Garassino, Y. Chen, M. Özgüroğlu, M. Dvorkin, D. Trukhin, G. Statsenko, K. Hotta, JH. Ji, MJ. Hochmair, O. Voitko, L. Havel, A. Poltoratskiy, G. Losonczy, N. Reinmuth, N. Patel, PJ. Laud, N. Shire, H. Jiang, L. Paz-Ares
520    9_
$a OBJECTIVES: In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall survival (primary endpoint) versus EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) at the interim analysis. Here we report patient-reported outcomes (PROs). MATERIALS AND METHODS: Treatment-naïve patients with ES-SCLC received 4 cycles of durvalumab plus EP every 3 weeks followed by maintenance durvalumab every 4 weeks until progression, or up to 6 cycles of EP every 3 weeks. PROs, assessed with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) version 3 and its lung cancer module, the Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), were prespecified secondary endpoints. Changes from baseline to disease progression or 12 months in prespecified key disease-related symptoms (cough, dyspnea, chest pain, fatigue, appetite loss) were analyzed with a mixed model for repeated measures. Time to deterioration (TTD) of symptoms, functioning, and global health status/quality of life (QoL) from randomization was analyzed. RESULTS: In the durvalumab plus EP and EP arms, 261 and 260 patients were PRO-evaluable. Patients in both arms experienced numerically reduced symptom burden over 12 months or until progression for key symptoms. For the improvements from baseline in appetite loss, the between-arm difference was statistically significant, favoring durvalumab plus EP (difference, -4.5; 99% CI: -9.04, -0.04; nominal p = 0.009). Patients experienced longer TTD with durvalumab plus EP versus EP for all symptoms (hazard ratio [95% CI] for key symptoms: cough 0.78 [0.600‒1.026]; dyspnea 0.79 [0.625‒1.006]; chest pain 0.76 [0.575‒0.996]; fatigue 0.82 [0.653‒1.027]; appetite loss 0.70 [0.542‒0.899]), functioning, and global health status/QoL. CONCLUSION: Addition of durvalumab to first-line EP maintained QoL and delayed worsening of patient-reported symptoms, functioning, and global health status/QoL compared with EP.
650    _2
$a monoklonální protilátky $7 D000911
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a cisplatina $x terapeutické užití $7 D002945
650    _2
$a etoposid $x terapeutické užití $7 D005047
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x farmakoterapie $7 D008175
650    _2
$a hodnocení výsledků péče pacientem $7 D000071066
650    _2
$a platina $x terapeutické užití $7 D010984
650    _2
$a kvalita života $7 D011788
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Garassino, Marina $u Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy $7 xx0280337
700    1_
$a Chen, Yuanbin $u Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI, USA
700    1_
$a Özgüroğlu, Mustafa $u Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
700    1_
$a Dvorkin, Mikhail $u BHI of Omsk Region Clinical Oncology Dispensary, Omsk, Russia
700    1_
$a Trukhin, Dmytro $u Odessa National Medical University, Odessa, Ukraine
700    1_
$a Statsenko, Galina $u Omsk Regional Cancer Center, Omsk, Russian Federation
700    1_
$a Hotta, Katsuyuki $u Okayama University Hospital, Okayama, Japan
700    1_
$a Ji, Jun Ho $u Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
700    1_
$a Hochmair, Maximilian J $u Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria
700    1_
$a Voitko, Oleksandr $u Kyiv City Clinical Oncological Centre, Kiev, Ukraine
700    1_
$a Havel, Libor $u Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Poltoratskiy, Artem $u Petrov Research Institute of Oncology, St Petersburg, Russian Federation
700    1_
$a Losonczy, György $u Semmelweis University, Budapest, Hungary
700    1_
$a Reinmuth, Niels $u Asklepios Lung Clinic, Munich-Gauting, Germany
700    1_
$a Patel, Nikunj $u AstraZeneca, Gaithersburg, MD, USA
700    1_
$a Laud, Peter J $u Statistical Services Unit, University of Sheffield, Sheffield, UK
700    1_
$a Shire, Norah $u AstraZeneca, Gaithersburg, MD, USA
700    1_
$a Jiang, Haiyi $u AstraZeneca, Gaithersburg, MD, USA
700    1_
$a Paz-Ares, Luis $u Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain
773    0_
$w MED00003160 $t Lung cancer $x 1872-8332 $g Roč. 149, č. - (2020), s. 46-52
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32961445 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20230109125905 $b ABA008
999    __
$a ok $b bmc $g 1690677 $s 1140365
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 149 $c - $d 46-52 $e 20200910 $i 1872-8332 $m Lung cancer $n Lung Cancer $x MED00003160
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options